Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next
New York, January 7, 2026, 05:25 EST — Premarket Moderna (MRNA) shares fell 1.4% to $35.15 in premarket trading on Wednesday, after jumping 10.9% in the previous session to close at $35.66. The stock hit an intraday high of $36.26 on Tuesday, with about 20.2 million shares traded. StockAnalysis The moves follow Moderna’s announcement on Monday that it has filed for marketing authorization — regulatory approval to sell — for its messenger RNA (mRNA) seasonal influenza vaccine, mRNA-1010, in the United States, Europe, Canada and Australia. Moderna said the filings were backed by Phase 3 data showing relative vaccine efficacy